Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study

Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients

(2019) J. Rogado et al.   EUROPEAN JOURNAL OF CANCER

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

(2018) Brigette B.Y. Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab

(2018) Daisuke Nishikawa et al.   Cancers

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

(2017) Shunsuke Teraoka et al.   Journal of Thoracic Oncology

A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

(2017) Naomi Kiyota et al.   ORAL ONCOLOGY

Excellent response to chemotherapy post immunotherapy

(2017) Ashish D. Dwary et al.   Oncotarget

Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy

(2017) Daiki Ogawara et al.   Thoracic Cancer

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer

(2015) Xuan Hong et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Assessing oncologic benefit in clinical trials of immunotherapy agents

(2010) R. K. Hales et al.   ANNALS OF ONCOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH